148
Participants
Start Date
May 31, 2009
Primary Completion Date
March 31, 2011
Study Completion Date
July 31, 2011
treprostinil diethanolamine
oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
placebo
The Hospital for Special Surgery, New York
North Shore-LIJ Health System, Lake Success
University of Pittsburgh, Pittsburgh
Georgetown University, Washington D.C.
Johns Hopkins University - Division of Rheumatology, Baltimore
Medical University of South Carolina, Charleston
University of Alabama - Arthritis Clinical Intervention Program, Birmingham
University of Toledo, Toledo
Cleveland Clinic Foundation, Cleveland
University of Indiana School of Medicine, Indianapolis
University of Michigan Scleroderma Program, Ann Arbor
Medical College of Wisconsin, Milwaukee
University of Minnesota, Minneapolis
Northwestern University - Feinberg School of Medicine, Chicago
University of Texas - Houston, Houston
Denver Medical Center, Aurora
University of Utah, Salt Lake City
Mayo Clinic Scottsdale, Scottsdale
UCLA, Los Angeles
Stanford University School of Medicine/Palo Alto VA Health Care System, Palo Alto
Virginia Mason Medical Center, Seattle
University of Connecticut Health Center, Farmington
Boston University School of Medicine, Boston
UMDNJ Clinical Research Center, New Brunswick
Dalhousie University - QEII Health Science Center, Halifax
St Joseph's Health Care, London
McGill University, Montreal
Clinical Sciences Center - University Hospital, Liverpool
Royal Free Hospital - Center for Rheumatology, London
Salford Royal Hospital, Manchester
Lead Sponsor
United Therapeutics
INDUSTRY